Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice

被引:25
作者
Cao, BJ [1 ]
Rodgers, RJ [1 ]
机构
[1] Univ Leeds, Sch Psychol, Ethopharmacol Lab, Leeds LS2 9JT, W Yorkshire, England
基金
英国惠康基金;
关键词
anxiety; elevated plus-maze; LY293284; LY315712; LY297996; 5-HT1A receptor; circadian factor; mice;
D O I
10.1007/s002130050703
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In contrast to the variable efficacy of 5-HT1A receptor full and partial agonists in animal models of anxiety, recent findings in our laboratory have revealed remarkably consistent anxiolytic-like effects for 5-HT1A receptor antagonists in the murine elevated plus-maze paradigm. In the present study, ethological techniques were used directly to compare the plus-maze profiles of three novel ligands varying in intrinsic efficacy at 5-HT1A receptors: LY293284 (full agonist; 0.01-0.3 mg/kg), LY315712 (partial agonist; 0.3-3.0 mg/kg); and LY297996 (antagonist; 0.03-10.0 mg/kg). At the lowest dose tested, LY293284 tended to enhance several indices of anxiety, whereas higher doses suppressed all active behaviours. Although few behavioural effects were observed with LY315712 under present test conditions, a selective reduction in risk assessment was apparent at 1.0-3.0 mg/kg. In contrast to these profiles, LY297996 (3.0-10.0 mg/kg) produced robust anxiolytic-like effects on conventional and ethological parameters but, importantly, did not alter general activity levels. These results provide further support for the anxiolytic potential of 5-HT1A receptor antagonists and are discussed in relation to possible factors underlying inter-laboratory variation in the effects of these agents in animal models of anxiety.
引用
收藏
页码:185 / 194
页数:10
相关论文
共 72 条
[21]  
COLLINSON N, 1996, J PSYCHOPHARMACOL, V10, pA46
[22]   ETHOPHARMACOLOGICAL ANALYSIS OF RAT BEHAVIOR ON THE ELEVATED PLUS-MAZE [J].
CRUZ, APM ;
FREI, F ;
GRAEFF, FG .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1994, 49 (01) :171-176
[23]  
DEVRY J, 1995, PSYCHOPHARMACOLOGY, V121, P1
[24]  
FILE SE, 1992, BIOL COUN S, P25
[25]  
File SE, 1996, J NEUROSCI, V16, P4810
[26]  
Fletcher A, 1996, BEHAV BRAIN RES, V73, P337
[27]   PHARMACOLOGICAL CHARACTERIZATION OF ENANTIOMERS OF 8-THIOMETHYL-2-(DI-N-PROPYLAMINO)TETRALIN, POTENT AND SELECTIVE 5-HT1A RECEPTOR AGONISTS [J].
FOREMAN, MM ;
FULLER, RW ;
LEANDER, JD ;
NELSON, DL ;
CALLIGARO, DO ;
LUCAITES, VL ;
WONG, DT ;
ZHANG, L ;
BARRETT, JE ;
SCHAUS, JM .
DRUG DEVELOPMENT RESEARCH, 1995, 34 (01) :66-85
[28]  
FOREMAN MM, 1994, J PHARMACOL EXP THER, V270, P1270
[29]   Serum corticosterone increases reflect enhanced uptake inhibitor-induced elevation of extracellular 5-hydroxytryptamine in rat hypothalamus [J].
Fuller, RW ;
Perry, KW ;
HemrickLuecke, SK ;
Engleman, E .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1996, 48 (01) :68-70
[30]   Behavioural and pharmacological characterisation of the canopy stretched attend posture test as a model of anxiety in mice and rats [J].
Grewal, SS ;
Shepherd, JK ;
Bill, DJ ;
Fletcher, A ;
Dourish, CT .
PSYCHOPHARMACOLOGY, 1997, 133 (01) :29-38